title: Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer.
abstract: OBJECTIVE
  Over the past decade, clinical trials have proved the efficacy of treatments for colorectal cancer (CRC). This study tracks dissemination of these treatments for patients diagnosed with stage II and III disease and compares risk of death for those who received guideline therapy to those who did not.
  
  
  METHODS
  We conducted a stratified randomly sampled, population-based study of CRC treatment trends in the United States. Multivariate models were used to explore patient characteristics associated with receipt of treatments. We pooled data with a previous study-patients diagnosed in 1987-1991 and 1995. Cox proportional hazards models were used to assess observed cause-specific and all-cause mortality.
  
  
  RESULTS
  In 2000, guideline therapy receipt decreased among stage III rectal cancer patients, but increased for stage III colon and stage II rectal cancer patients. As age increased, likelihood of receiving guideline treatment decreased (p < 0.0001). Overall, race/ethnicity was significantly associated with guideline therapy (p = 0.04). Rectal patients were less likely to have received guideline treatment. Consistent with randomized clinical trial findings, all-cause mortality was lower in patients who received guideline therapy, regardless of Charlson comorbidity score.
  
  
  CONCLUSIONS
  Mortality was decreased in patients receiving guideline therapy. Although, rates of guideline-concordant therapy are low in community clinical practice, they are apparently increasing. Newer treatment (oxaliplatin, capecitabine) started to disseminate in 2000. Racial disparities, present in 1995, were not detected in 2000. Age disparities remain despite no evidence of greater chemotherapy-induced toxicity in the elderly. More equitable receipt of cancer treatment to all segments of the community will help to reduce mortality.
authors.affiliation: Surveillance Research Program, DCCPS, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: Deirdre P
authors.initials: DP
authors.lastname: Cronin
authors.forename: Linda C
authors.initials: LC
authors.lastname: Harlan
authors.forename: Arnold L
authors.initials: AL
authors.lastname: Potosky
authors.forename: Limin X
authors.initials: LX
authors.lastname: Clegg
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Stevens
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Mooney
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D018426:SEER Program; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents